AU2022293581A1 - ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE - Google Patents

ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE Download PDF

Info

Publication number
AU2022293581A1
AU2022293581A1 AU2022293581A AU2022293581A AU2022293581A1 AU 2022293581 A1 AU2022293581 A1 AU 2022293581A1 AU 2022293581 A AU2022293581 A AU 2022293581A AU 2022293581 A AU2022293581 A AU 2022293581A AU 2022293581 A1 AU2022293581 A1 AU 2022293581A1
Authority
AU
Australia
Prior art keywords
seq
antibody
cdr
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022293581A
Other languages
English (en)
Inventor
Katerina Akassoglou
Jeffrey Stavenhagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therini Bio Inc
Original Assignee
Therini Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therini Bio Inc filed Critical Therini Bio Inc
Publication of AU2022293581A1 publication Critical patent/AU2022293581A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022293581A 2021-06-18 2022-06-20 ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE Pending AU2022293581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212409P 2021-06-18 2021-06-18
US63/212,409 2021-06-18
PCT/US2022/034188 WO2022266539A2 (en) 2021-06-18 2022-06-20 ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE

Publications (1)

Publication Number Publication Date
AU2022293581A1 true AU2022293581A1 (en) 2024-01-25

Family

ID=84526539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022293581A Pending AU2022293581A1 (en) 2021-06-18 2022-06-20 ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE

Country Status (6)

Country Link
US (1) US20240279357A1 (https=)
EP (1) EP4355772A4 (https=)
JP (1) JP2024522237A (https=)
AU (1) AU2022293581A1 (https=)
CA (1) CA3222934A1 (https=)
WO (1) WO2022266539A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116235A2 (en) * 2004-05-07 2005-12-08 The Regents Of The University Of California Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment
HUE031571T2 (en) * 2009-10-02 2017-07-28 Univ California Monoclonal antibodies
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof
SI3215527T1 (sl) * 2014-11-05 2025-04-30 Annexon, Inc. Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
SI3445785T1 (sl) * 2016-04-18 2022-11-30 Faron Pharmaceuticals Oy, Humanizirana protitelesa proti CLEVER-1 in njihova uporaba
MX2021001268A (es) * 2018-08-01 2021-09-08 Imcheck Therapeutics Sas Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.

Also Published As

Publication number Publication date
JP2024522237A (ja) 2024-06-11
US20240279357A1 (en) 2024-08-22
EP4355772A4 (en) 2025-07-30
CA3222934A1 (en) 2022-12-22
WO2022266539A9 (en) 2023-09-14
WO2022266539A3 (en) 2023-01-26
WO2022266539A2 (en) 2022-12-22
EP4355772A2 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US12358979B2 (en) Antibodies that bind interleukin 13 and methods of use
US12269894B2 (en) Antibodies which bind human fibrin or fibrinogen γC domain and methods of use
US20240279357A1 (en) ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
WO2024173847A2 (en) Antibodies that bind interleukin 4 receptor alpha and methods of use
EP4705347A2 (en) Antibodies that bind ox40l and methods of use
WO2022159776A1 (en) Antibodies which bind human fibrin and methods of use
WO2025265071A1 (en) Antibodies that bind tslp and methods of use
WO2024076993A2 (en) Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
US20260109756A1 (en) Multi-specific antigen binding proteins which bind human fibrin or fibrinogen yc domain and vascular endothelial growth factor and methods of use
WO2026085202A1 (en) Antibodies that bind tslp and methods of use
EA052830B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ДОМЕН γC ФИБРИНА ИЛИ ФИБРИНОГЕНА ЧЕЛОВЕКА, И СПОСОБЫ ПРИМЕНЕНИЯ
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
WO2025212751A1 (en) Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use
WO2026060117A1 (en) Bispecific antibodies binding to tl1a and osmr
HK40130326A (zh) 结合白介素4受体α的抗体和使用方法